ABSTRACT
score (p-value <0.001). The mean MRS total score at the baseline was 22 .43 and decreased to 5.29 after treatment at 84th day, and further reduced to 5.06 at the 14th week (follow-up period without trial interventions). The improvements of MENQOL in four domains, viz., vasomotor, psychosocial, sexual, and physical, at the end of 12th week and 14th week were also significant (p-value <0.001) in comparison with the baseline. Further, all the safety parameters like liver function tests and kidney function tests remained within the normal limits throughout the trial period and no adverse events or adverse drug reaction were reported, which confirm the clinical safety of the trial drugs.
INTRODUCTION
Women, who constitute half of the world's population, are currently enjoying a life expectancy of 84.3 years approximately in developed countries. 1 Menopause is a natural phenomenon and mostly occurs at the age of 50 to 52 years in a woman. 2 Different stages, i.e., perimenopause, menopause, and postmenopause, comprise a half or a third of a woman's life, particularly in developing countries. 3 It is characterized by an altered hormonal status and a subsequent decrease in quality of life, affecting each woman differently. Specifically, the decline and eventual cessation of estrogen production are associated with the appearance of uncomfortable symptoms (hot flushes, night sweats, breast tenderness, vaginal dryness, irregular menses, mood changes, and vaginal atrophy) as well as pathologies, such as osteoporosis, heart disease, hypercholesterolemia, endothelial dysfunction, vascular inflammation, hyperglycemia, and depression. 4 Clinical studies indicate that the use of hormone replacement therapy (HRT) in menopause needs to be carefully assessed and risks and benefits of the therapy should be evaluated by the clinician for each individual woman. Herbal preparations, food supplements, healthy living, and healthy mental status were mentioned as possible alternatives for managing menopausal symptoms.
In Ayurveda, Rajonivritti kala (the period of permanent cessation of menstrual cycle) is considered as 50 years 5, 6 mentioned by all classical texts without any controversy. It is a consequence of Jaraawastha (senility), 7 and Vata remains dominant during this period. 8 Ashokarishta,
Ashvagandha Churna and Pravala Pishti are among thousands of traditional Ayurvedic formulations which are widely used to treat ailments in women. Ashokarishta, a polyherbal formulation, contains herbs having Hridya
properties. Further, Ashoka (Saraca asoca Roxb. willd), the principal ingredient of the formulation has the action, viz., Daha shamak (alleviates burning sensation in the body), pittahara due to its sheeta guna. 9 Ashvagandha churna is a well-known Balya (immune modulator), Vayasthapaka (rejuvenator), and Manastarpaka (brain tonic). Pravala pishti is having Pittahara property and is a rich source of calcium. Due to above actions and uses and as these drugs are in use since long safely and effectively, their efficacy in the present context needs to be evaluated. Keeping this in view, the present study was designed to establish the efficacy of Ashokarishta, Ashvagandha Churna and Pravala Pishti in the management of menopausal syndrome.
OBJECTIVES
The primary objective was to assess the clinical efficacy of Ashokarishta, Ashvagandha Churna and Pravala Pishti in the management of menopausal syndrome and secondary objective was to assess the changes in the quality of life of the women with menopausal syndrome.
MATERIALS AND METHODS

Study Design and Setting
This was a multicenter single-arm study conducted at three 
Study Participants
Total 116 menopausal women were recruited for the trial from the outpatient departments of all the participating centers after obtaining written informed consent. Patients were screened in accordance with inclusion and exclusion criteria mentioned in the protocol.
Inclusion Criteria
Women between the age of 40 and 55 years; with amenorrhea for ≥12 months; Kupperman menopausal index score ≥15; levels of follicle-stimulating hormone (FSH) ≥20 IU/L, and endometrial thickness ≤5 mm and who were willing to participate were included in the study.
Exclusion Criteria
Patients with evidence of malignancy, who has had surgical menopause, or those who were diagnosed with mental illness were excluded. Moreover, patients suffering from systemic diseases, such as diabetes mellitus, hypertension, rheumatoid arthritis, coronary heart disease, patients with concurrent serious hepatic disorder (defined as aspartate aminotransferase and/or alanine aminotransferase, total bilirubin, alkaline phosphatase >2 times upper normal limit) or renal disorders (defined as serum creatinine >1.2 mg/dL), chronic obstructive pulmonary disease, hypothyroidism, and any other major illness were also vetoed from the study. The women on prolonged (>6 weeks) medication with corticosteroids, antidepressants, anticholinergics, or any other drugs that may have an influence on the outcome of the study; alcoholics and/or drug abusers; and those who have participated in any other clinical trial in the past 6 months of screening were also excluded.
Study Interventions
Ashokarishta, 10 Ashvagandha churna, 11 and Pravala pishti, 12 three classical Ayurvedic formulations, were procured from Good Manufacturing Practice-certified Ayurvedic pharmaceutical industries and standardized following the standard laid in Ayurvedic Pharmacopoeia of India.
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Ashokarishta was administered orally in a dose of 25 mL twice a day with equal quantity of water after food. Ashvagandha churna (3 gm) and Pravala pishti (one capsule of 250 mg) were administered orally twice a day with milk just half an hour before food intake. These treatment schedules were continued for 12 weeks followed by sub-JRAS sequent 2 weeks follow-up without trial interventions.
Study Procedure
On the enrollment day at baseline (visit 1), patients' demographic profile, medical history, general physical and systemic examination, assessment of clinical/Ayurvedic parameters and scoring of menopause rating scale (MRS), menopause-specific quality of life (MENQOL) questionnaire were recorded. Trial drugs and drug compliance report form was also given and the subsequent visits were planned at an interval of 2 weeks [14th day (visit 2), 28th day (visit 3), 42nd day (visit 4), 56th day (visit 5), 70th day (visit 6), and 84th day (visit 7)]. Patients were assessed and study medications were given at each subsequent visit till 84th day. In addition to 12 weeks (84 days) intervention period, a without drug follow-up at 14th week was also scheduled. Details of clinical assessment and study schedule are given in Flow Chart 1. Data of all the patients were recorded in predesigned case report forms (CRFs) and were also entered in electronic formats (e-formats) designed in MS-Excel with many data validation checks to ensure correct data entry. The e-formats and xerox of the CRFs along with the scorings and laboratory investigation reports of the patients were sent by the participating centers to the Council's headquarters on a weekly basis for the purpose of clinical trial monitoring.
Out of the total 116 patients enrolled in the study, 7 dropped out during the course of the study. Intentionto-treat analysis was done and the data of all those patients who have completed at least 14th day visit were imputed by last-observation carried-forward (LOCF) method. Patients who dropped out after baseline visit only were excluded from analysis. Hence, data of a total 115 patients were used for statistical analysis. Flow Chart 2 shows the outflow of the patients in the study.
Efficacy Evaluation through Outcome
The primary outcome measure was change in menopausal symptoms using MRS score and was assessed at the baseline, end of 12th week, and the end of 14th week. The MRS has 11 symptoms, and each was rated on a 5-point scale of severity. It is also divided into three subscales: somatic, psychological, and urogenital. The secondary outcome measure was changes in the quality of life of the study participants from the baseline and assessed at the end of 12th week and 14th week by using MENQOL questionnaire. It contains 29 items with four domains: vasomotor, psychosocial, physical, and sexual scores range from 0 to 6. Lower scores indicate better quality of life.
Flow Chart 1: Study schedule
Statistical Analysis
The efficacy and safety parameters were analyzed according to the intention-to-treat analysis. Missing values were imputed by the LOCF method. Statistical analysis was performed using Statistical Packages for Social Sciences. Statistical significance was defined as p-value <0.05. Primary and secondary outcome measures; changes in the scores for MRS and MENQOL questionnaire from the baseline to 12 weeks were analyzed by using paired t-test.
RESULTS
Data of 115 women fulfilling the inclusion criteria were used for statistical analysis. The baseline demographic data and outcome measures of the participants are summarized in Table 1 . Data revealed that the mean [standard deviation (SD)] age of the participants was 49.24 (3.64) years; 85.2% of the participants were married, and 78.3% were housewives; 64.3% of the participants belonged to urban area, and 75.7% of patients had sleep disturbances.
Effect of the Trial Drugs on the Score of MRS
At baseline, the MRS total score was 22.43 (8.24) and 36.82% reduction was seen after 4 weeks, 63.31% after 8 weeks, 76.41% after 12 weeks, and 77.44% after 14 weeks. The effect of therapy has shown statistically significant (p-value <0.001) decrease in MRS total score ( Table 2) .
The test formulations also showed statistically significant (p < 0.001) improvement in all the three MRS subscale scores (somatic, psychological, and urogenital symptoms) at all time intervals when compared with their respective baseline score. In somatic subscale, at the end of 12 weeks, the score was 2.45 (3.21) and 72.87% reduction was seen. At the end of 14th week, the score was 2.23 (1.67) and 75.3% reduction was seen. Further, in psychological and urogenital subscales, the effect of the treatment was 74.17% (2.58 ± 2.01) and 85% (0.51 ± 1.13) respectively, at the end of 12 weeks and 75.87% (2.41 ± 2.09) and 87.35% (0.43 ± 0.98) at the end of 14 weeks respectively (Graph 1).
Effects of Trial Drugs on Total and Different Domains of MENQOL Score
The effect of treatment on MENQOL is shown in Graph 2 and Table 2 . A significant reduction in total MENQOL scores was observed after the treatment of 12 weeks and also at the end of 14 weeks (2-week follow-up period) in comparison to the baseline. Further, in vasomotor domain, the reduction in the symptoms at the end of 12 weeks was 2.3 (2.79), i.e., 77.84%, and 14 weeks 1.91 (2.5), i.e., 81.6% in comparison to baseline score, i.e., 10.38 (4.9); on psychosocial domain the reduction in the symptoms at the end of 12 weeks was 8.75 (6.54), i.e., 60.8% in comparison with baseline score, i.e., 21.0 (7.54). Similarly, in physical domain, the reduction in the symptoms at the end of 12 weeks was 18.2 (11.8), i.e., 57.7%, and at the end of 14 weeks 16.9 (11.8), i.e., 60.8% in comparison with baseline, i.e., 42.98 (13.1). In sexual domain, the reduction of symptoms from baseline score was 3.6 (5.1) to 0.8 (2.33), i.e., 78.1% at the end of 12 weeks and 0.7 (2.2), i.e., 80.6% at the end of 14 weeks.
Effect of the Drugs on Safety Parameters
The effect of this treatment on liver function tests and renal function tests was assessed at baseline and at 84th day. The values were within range during the entire period (Table 3 , Graphs 3 to 5). These observations validate that these classical drugs are safe for human use. Further, no adverse drug effect or adverse events were reported during the treatment period. The adverse drug reactions (e.g., headache, dizziness, nausea, vomiting)/ events if any were also recorded during study period in a prescribed format. 
Flow Chart 2: Outflow of the patients in the study
DISCUSSION
In this study, Ashokarishta, Ashvagandha Churna and Pravala Pishti in a combination have shown significant efficacy to reduce the signs and symptoms in menopausal women.
The total MRS score and scores of three subscales have been significantly decreased at 12th week (84th day) and at 14th week as compared with the baseline score. Further, there was significant improvement in the MENQOL scales at the end of 12th week in comparison to initial values.
Oxidative stress plays an integral part of the ageing process and results from the overproduction of free radicals, which overwhelm the body's antioxidant defense mechanisms. The decline in antioxidant level combined with a gradual loss of estrogens in the female body is highly associated with the various sequel of menopausal syndrome. 14, 15 Ashvagandha is well known for its antioxidant, adaptogenic, rasayana (rejuvenating), and antistress effects and thus help in improving MRS total score and MENQOL score in the present study. [16] [17] [18] Earlier studies suggest the potential role of Withania somnifera (Ashvagandha) in improving the quality of life in breast cancer patients and related problems. 19 The menopause-induced hormonal deficit has been linked to 22 which are supposed to be beneficial in improvement of various parameters in the present study. Ashokarishta is one of the Ayurvedic polyherbal-fermented liquid formulations known to cure gynecological disorders. It is considered as an ideal rejuvenator. Ashokarishta has good free radical scavenging, reducing power, and superoxide scavenging activity. 23 The test drugs significantly decreased the FSH level, while showing nonsignificant increase in estradiol content as compared with the baseline values. Previous studies suggest that serum estrogen concentration decreased significantly with the increase in age and a steeper decline was observed at higher age, while FSH concentration increased significantly with advancement of age and a steeper increase was observed at higher age. 24 Pravala pishti has pittahar property and is also a rich source of calcium. In the present study, Pravala is used with herbal phytoestrogen for better result in menopausal syndrome. The study conducted earlier on the above formulations also showed a significant result in both somatic and psychological complaints in women. 25 But in that study, the sample size was less in comparison to the present study. Further, it is observed that all the test drugs are clinically safe to use as no significant changes were seen in any of the safety parameters, i.e., kidney function and liver function. No adverse drug reaction or events were also reported during the treatment period.
Hence, it is suggested that Ashokarishta, Ashvagandha Churna and Pravala Pishti are clinically safe.
CONCLUSION
From the present study, it is concluded that Ashokarishta, Ashvagandha Churna and Pravala Pishti are effective in the treatment of menopause-associated symptoms and can promote the quality of life of menopausal woman. Hence, these Ayurvedic formulations can be used effectively for the management of menopausal symptoms in place of HRT and other therapies. Further, it is suggested that a randomized clinical trial may be conducted to corroborate the result of this study. 
